Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women

Archives of Gynecology and Obstetrics

Volumn 266, Issue 1, 2002, Pages 38-43

  Sendag, F ^a   Karadadas, N ^a   Ozsener, S ^a   Bilgin, O ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Hormone replacement therapy; Lipids; Lipoproteins; Transdermal delivery

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED; FEMALE; FOLLICLE STIMULATING HORMONE; HUMAN; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; LUTEINIZING HORMONE; MIDDLE AGE; NORETHINDRONE; POSTMENOPAUSE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0036936843     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007497     Document Type: Article

References (40)

1. Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V (1993) Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 17:191-196
2. Austin M, Hokanson J, Edwards K (1998) Hypertriglyceridaemia as a cardiovascular risk factor. Am J Cardiol 81:7B-12B
3. Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265:1861-1867
4. Basdevant A, De Lignieres B, Guy-Grand B (1983) Differential lipemic and hormonal response to oral and parenteral 17β estradiol in postmenopausal women. Am J Obstet Gynecol 147:77-81
5. Bush TL, Miller VT (1987) Effects of pharmacological agents used during menopause: impact on lipids and lipoproteins. In: Mishell DR (ed) Menapouse: physiology and pharmacology. Year Book Medical Publishers, Chicago, pp 187-208
6. Bush T, Barret-Connor E, Cowan L et al. (1987) Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study. Circulation 75:1102-1109
7. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL (1986) Biologic effects of transdermal estradiol. N Engl J Med 314:1615-1620
8. Cortellaro M, Nencioni T, Boschetti C, Ortolans S, Buzzi F et al. (1991) Cyclic hormone replacement therapy after the menopause: transdermal versus oral treatment. Eur J Clin Pharmacol 47:555-559
9. Crook D, Stevenson JC (1993) Hormone replacement and cardiovascular risk factors. N Engl J Med 329:1041-1042
10. Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead MI, Wynn V (1992) Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 166:950-955
11. Drexel H, Amann F, Beran J (1994) Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 90: 2230-2235
12. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18:499-502
13. Gelfand M, Fugere P, Bissonnette F (1997) Cardiovascular risk factors during sequentially combined 17-beta oestradiol and dydrogesterone (femoston): results from a one year study in postmenopausal women. Maturitas 26:125-132
14. Godsland IF, Wynn V, Crook D, Miller NE (1987) Sex, plasma lipoproteins and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J 114:1467-1503
15. Gokmen O, Yapar Eyi EG (1999) Hormone replacement therapy and lipid-lipoprotein concentrations. Eur J Obstet Gynecol Reprod Biol 85:31-41
16. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser M (1997) Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomized study. Br J Obstet Gynaecol 104:708-717
17. Henderson B, Ross R, Lobo R, Pike M, Mack T (1988) Reevaluating the role of progestin therapy after the menopause. Fertil Steril 49:9S-15S
18. Hokanson J, Austin M (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based studies. J Cardiovasc Risk 3:213-219
19. Jacobs DJ, Mebane I, Bangdiwala S, Criqui M, Tyroler H (1990) High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 131:32-47
20. La Rosa JC (1988) The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol 158: 1619-1629
21. Lindgren R, Berg G, Hammar M, Larsson-Cohn U, Olsson AG (1992) Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. Eur J Obstet Gynecol Reprod Biol 47:213-221
22. Lobo RA (1991) Clinical review 27. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73:925-930
23. Lobo RA, Speroff L (1994) International consensus conference on postmenopausal hormone replacement therapy and the cardiovascular system. Fertil Steril 61:592-595
24. Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P (1998) Effects of oral and transdermal hormone replacement therapy on lipoprotein (a) and lipids: a randomized controlled trial. Menopause 5:157-162
25. Mount J, Kearney E, Rosseneu M, Slavin B (1988) Immunoturbidimetric assays for serum apolipoproteins AI, B using Cobas Bio centrifugal analyser. J Clin Pathol 41:471-474
26. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C (1989) Risk for endometrial cancer after treatment with estrogen alone or in conjunction with progestogens: results of a prospective study. BMJ 298:147-151
27. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE (1981) Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1:858-860
28. Ross R, Paganini-Hill A, Mack T, Henderson B (1989) Cardiovascular benefits of estrogen replacement therapy. Am J Obstet Gynecol 160:1301-1306
29. Roy S, Krauss RM, Mishell DR, Casagrande EJ, Pike MC (1981) The effect on lipids and lipoproteins of a contraceptive vaginal ring containing levonorgestrel and estradiol. Contraception 24:429-449
30. Rozenberg S, Ylikorkala O, Arrenbrecht S (1997) Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil Womens Med 42:376-387
31. Spencer C, Crook D, Ross D, Cooper A, Whitehead M, Stevenson J (1999) A randomized comparison of the effects of oral versus transdermal 17β-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. Br J Obstet Gynaecol 106:948-953
32. Stampfer MJ, Colditz GA (1991) Estrogen replacement therapy and coronary artery disease: a quantitative assessment of the epidemiological evidence. Prev Med 20:47-63
33. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal oestrogen therapy and cardiovascular disease. Ten year follow-up from the Nurses' Health Study. N Engl J Med 325:756-762
34. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA (1988) A randomized comparison of non-oral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 159:1540-1546
35. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI (1993) Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Stud 38:30-35
36. The writing group for the PEPI Trial (1995) Effects of estrogen and estrogen-progesterone regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 273:199-208
37. Tikkanen MJ, Kuusi T, Nikkila EA, Sipinen S (1986) Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins: a review. Maturitas 8:7-17
38. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204
39. Warnick G, Albers J (1978) A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19:65-76
40. Whitehead M, Fraser D, Schenkel L, Crook D, Stevenson J (1990) Transdermal administration of oestrogen/progestogen hormone replacement therapy. Lancet 335:310-312